<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The pathophysiology of the <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) involves disturbed regulation of <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, proliferation and differentiation as well as immune surveillance </plain></SENT>
<SENT sid="1" pm="."><plain>Increasing data suggest that <z:chebi fb="0" ids="9168">sirolimus</z:chebi> might affect these pathways positively, thus being of possible therapeutic benefit in patients with this disease </plain></SENT>
<SENT sid="2" pm="."><plain>Nineteen patients (n = 19) with a median age of 72 years (range 54-80 years) diagnosed with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> received <z:chebi fb="0" ids="9168">sirolimus</z:chebi> orally with a target blood concentration of 3-12 ng/ml </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="9168">Sirolimus</z:chebi> was administered for a median of 3.7 months (range 0.3-11 months) </plain></SENT>
<SENT sid="4" pm="."><plain>Three patients [1 x refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>)-2, 1 x <z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB-1</z:e>, 1 x refractory cytopenia with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath>] showed either a major (1 x platelet, 1 x neutrophil) or a minor (1 x erythroid, 2 x platelet) haematological response according to International Working Group criteria </plain></SENT>
<SENT sid="5" pm="."><plain>Major side-effects were <z:e sem="disease" ids="C0020473" disease_type="Disease or Syndrome" abbrv="">hyperlipidaemia</z:e> (n = 4), <z:hpo ids='HP_0010280'>stomatitis</z:hpo> (n = 3), <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> (n = 2) and <z:hpo ids='HP_0000010'>urinary tract infection</z:hpo> (n = 1) </plain></SENT>
<SENT sid="6" pm="."><plain>These data suggest that <z:chebi fb="0" ids="9168">sirolimus</z:chebi> has activity in a subset of patients with more advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>